You are here: Home ยป Archives for Biotech

Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials

Highlights:

  • Designed to transform clinical trial operations for sponsors, sites and study teams
  • Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality
  • Builds on Fortrea’s flagship platform Xcellerate® to deliver near-real-time, role-based insights

DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations.

By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality.

An Innovative, Intelligent Suite of Clinical Solutions
FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate® platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem.

The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS).

FIT solutions are arranged into three pillars:

  • Lifecycle: Deliver Trials Faster with Confidence
    Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF.
  • Foresight: Turn Data into Actionable Insights
    Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight.
  • Companion: Empowering Study Teams to Work Smarter
    Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration.

“We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus,” said Chief Information Officer Alejandro Martinez Galindo. “Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk.”

Xcellerate® Anchors the Intelligent Suite
Xcellerate®, Fortrea’s platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering.

Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate® can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research.

“We expect these Xcellerate® enhancements and the broader FIT platform will be game changers for our study teams and our clients,” said Chief Operating Officer and President, Clinical Development Mark Morais. “Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us—all of which can make the difference in getting life-changing treatments to patients faster and more efficiently.”

Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:
Jennifer Minx (Media) – 919-410-4195, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
Tracy Krumme (Investors) – 984-385-6707, [email protected]


GLOBENEWSWIRE (Distribution ID 9685027)

Nucleus Brings Genetic Optimization to India and the Middle East Through Leading IVF Networks

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced joint ventures with Indira IVF, India’s largest IVF service provider, and Abu Ghosh Fertility Group, one of the highest-volume fertility networks in the Middle East, including the Shmaisani Fertility Center.

Through these partnerships, Nucleus will embed a new layer of genetic insight across preconception and embryo screening — enabling families to plan for their future child’s long-term health and longevity when choosing an embryo.

About The Partnerships

Indira IVF is India’s largest IVF service provider, performing nearly 42,000 IVF cycles in the last fiscal year across over 160 clinics. The Abu Ghosh Fertility Group serves patients across Jordan and the broader region. The network is led by Dr. Hilal Abu Ghosh, one of the region’s leading fertility specialists.

Spanning major fertility markets, both organizations are now part of the Nucleus IVF+ Network — a global group of IVF clinics integrating Nucleus into clinical care. At these practices, Nucleus will become part of routine IVF workflows, rolling out the technology across India and the Middle East.

In practice, that means screening of both parents and embryos will extend beyond rare inherited conditions to include broader insight into lifelong health risks such as cancer, heart disease, and diabetes.

“The instinct to give your child the best start transcends every culture, and the demand we saw from families in India and the Middle East reflects that,” said Kian Sadeghi, founder and CEO of Nucleus Genomics. “We’re excited to work alongside Indira and Abu Ghosh to support patients in building generational health.”

“Across India, the need for fertility care continues to grow, and at Indira IVF, the focus remains on strengthening patient care through the thoughtful integration of technology alongside clinical expertise,” said Dr. Kshitiz Murdia, CEO of Indira IVF. “Our association with Nucleus Genomics reflects a continued effort to improve care pathways and support families on their journey to parenthood.”

A Shift Toward Genetic Optimization in IVF

These partnerships reflect a broader shift in family planning. Across the world, families are asking for deeper genetic insight, and IVF clinics are responding by bringing Nucleus directly into their care.

Demand is particularly strong in regions facing high chronic disease burdens¹. In India, non-communicable diseases account for more than 60% of deaths, including high rates of type 2 diabetes², early heart disease³, and hypertension⁴. Across the Middle East, non-communicable diseases account for roughly 74% of deaths, with cardiovascular disease responsible for more than one-third of fatalities⁵.

Through Nucleus, Indira and Abu Ghosh are increasing the scope of care in India and the Middle East, signaling that genetic optimization is becoming the foundation to modern IVF globally.

“By combining Abu Ghosh Fertility Group’s clinical expertise in reproductive medicine with Nucleus Genomics’ cutting-edge genomic technologies, this initiative seeks to give families more informed options when selecting embryos and planning healthier futures,” said Dr. Hilal Abu Ghosh of Abu Ghosh Fertility Group. “We’re proud to offer new approaches to embryo evaluation that help clinicians and families make more informed reproductive decisions.”

Expanding the Nucleus IVF+ Network

This partnership follows rapid growth of the Nucleus IVF+ Network. Nucleus has worked with 25 clinics globally, including official IVF+ partners such as CDelaF in Mexico, Beverly Hills Fertility in Los Angeles, and Neway Fertility in New York. It also builds on the company’s recent Preview launch, which expanded carrier screening from edge-case diseases to everyday health risk.

In line with national regulations, Nucleus’ offerings in India will exclude trait selection and do not disclose embryo sex. The analysis focuses solely on serious, medically relevant health risk information, aligning with local legal standards.

About Nucleus Genomics

Nucleus Genomics helps couples plan and have their best baby. Its products span advanced carrier screening, embryo analysis, and an integrated IVF care experience, with a focus on building generational health. Nucleus has raised more than $32 million to date with investors including Founders Fund, Seven Seven Six, Samsung Next, and Quiet Capital. To learn more about Nucleus, visit https://mynucleus.com.

About Indira IVF

Indira IVF operates 160+ centers across India and performed nearly 42,000 IVF cycles in the last fiscal year. The organization employs more than 3,000 people. Incorporated in 2015 in Udaipur, the organization works to expand access to fertility care, and reduce stigma around infertility, alongside clinical training through the Indira Fertility Academy. For more information, visit https://www.indiraivf.com.

About Abu Ghosh Fertility Group
Abu Ghosh Fertility Group is a leading reproductive medicine and IVF provider based in Amman, Jordan. Founded and led by Dr. Hilal Abu Ghosh, the center specializes in advanced assisted reproductive technologies including IVF, ICSI, and reproductive genetic testing. The group integrates modern embryology laboratories with cutting-edge genomic technologies to support evidence-based fertility care for patients from Jordan and across the Middle East. Abu Ghosh Fertility Group is committed to advancing reproductive medicine through clinical excellence, research collaborations, and the adoption of innovative genomic approaches to improve reproductive outcomes.

Press Contact
Nucleus Genomics
[email protected] 

¹ Based on Nucleus patient and clinic data.

² Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-2938.

³ Prabhakaran D, Singh K, Roth GA, et al. Cardiovascular diseases in India compared with the United States. J Am Coll Cardiol. 2018;72(1):79-95.

⁴ Geldsetzer P, Manne-Goehler J, Theilmann M, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;178(3):363-372.

⁵ Population Reference Bureau. Curbing the noncommunicable disease epidemic in the Middle East and North Africa. Population Reference Bureau; 2023.


GLOBENEWSWIRE (Distribution ID 9678432)

Curia renforce ses capacités de production à Glasgow et consolide sa plateforme de développement de lignées cellulaires

ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) — Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production pharmaceutique stérile de Glasgow, au Royaume-Uni, ainsi que la consolidation de sa plateforme propriétaire dédiée au développement de lignées cellulaires.

Le site de Glasgow, au Royaume-Uni, est réputé dans tout le secteur pour son expertise de plus de 25 ans en formulation, en développement de procédés de lyophilisation, ainsi qu’en opérations de remplissage aseptique et de finition stérile, en particulier pour les conjugués anticorps-médicament (CAM) et d’autres produits hautement actifs. L’extension en cours devrait être finalisée au début de l’année 2027. Cet investissement prévoit l’intégration d’une ligne de remplissage de flacons sous isolateur conforme aux exigences de l’Annexe 1, ainsi que d’un lyophilisateur. À l’issue des travaux, le site de Glasgow disposera d’une capacité de remplissage pouvant atteindre 20 000 flacons par lot et sera -en mesure de soutenir de futures opérations de remplissage commercial à petite -échelle.

« Cette extension du site de Glasgow s’inscrit dans un contexte où Curia finalise parallèlement une importante extension de son site d’Albuquerque, au Nouveau-Mexique, dédié à la fabrication commerciale de médicaments », a indiqué Ron Aungst, vice-président, opérations de la division Produits pharmaceutiques. « Curia a d’ores et déjà sécurisé les équipements critiques à long délai d’approvisionnement nécessaires à la bonne exécution du projet d’extension de Glasgow, sans qu’aucune perturbation des opérations en cours ne soit anticipée durant la phase de déploiement. »

Curia a également consolidé ses capacités de développement de substances médicamenteuses à usage clinique grâce à l’optimisation de sa plateforme de développement de lignées cellulaires (CLD). Sur son site de Hopkinton, dans le Massachusetts, l’offre CLD a été enrichie par l’intégration d’une technologie d’intégration semi-ciblée, libre de droits de propriété intellectuelle, permettant d’atteindre des titres jusqu’à 6 fois supérieurs à ceux obtenus avec les approches d’intégration aléatoire. La plateforme stable de Curia, CHO-GSN®, repose sur la même lignée cellulaire parentale que sa plateforme transitoire, TunaCHO®, offrant ainsi aux partenaires une transition plus efficiente entre les phases de découverte et la production conforme aux BPF.

« Notre division des produits biologiques a toujours proposé des capacités intégrées de bout en bout, et nous nous réjouissons de mettre à la disposition de nos partenaires une lignée cellulaire leur permettant d’accélérer leur progression vers la fabrication clinique en phase précoce, tout en réduisant les coûts », a déclaré Jamie Grabowski, président, Recherche et Développement. « Grâce à des modalités de licence adaptées aux entreprises de biotechnologie, cette lignée cellulaire repensée constituera un levier essentiel pour accompagner efficacement nos partenaires jusqu’aux étapes de commercialisation. »

À propos de Curia
Curia est une organisation de recherche, de développement et de fabrication sous contrat (ou CDMO pour Contract Development and Manufacturing Organization) forte de plus de 30 ans d’expérience à son actif. Elle exploite un réseau intégré de plus de 20 sites à travers le monde et emploie quelque 3 100 collaborateurs travaillant en partenariat avec des clients biopharmaceutiques pour mettre sur le marché des traitements qui changent véritablement la vie des gens. Nos offres en matière de petites molécules, d’API génériques et de produits biologiques couvrent le cycle complet, de la découverte à la commercialisation, et intègrent des capacités réglementaires, analytiques et de remplissage et finition stérile. Nos scientifiques, nos experts en processus ainsi que nos installations conformes aux réglementations applicables apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous exécutons toutes les étapes pour accélérer vos recherches et améliorer la vie des patients. Consultez notre site à l’adresse curiaglobal.com.

Contact de l’entreprise :
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9675601)

Curia erweitert seine Produktionskapazitäten in Glasgow und verbessert seine Plattform zur Entwicklung von Zelllinien

ALBANY, New York, March 19, 2026 (GLOBE NEWSWIRE) — Curia, ein führendes Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CDMO), gab heute Fortschritte bei der Erweiterung seiner Anlage für sterile Arzneimittel in Glasgow (Vereinigtes Königreich) sowie Verbesserungen an seiner firmeneigenen Plattform für die Zelllinienentwicklung bekannt.

–Der Standort in Glasgow, Vereinigtes Königreich, ist in der gesamten Branche für seine mehr als 25-jährige Erfahrung in den Bereichen Formulierung, Entwicklung von Gefriertrocknungsverfahren und sterile Abfüll- und Konfektionierungsverfahren bekannt, einschließlich ADCs und anderer hochwirksamer Produkte. Die derzeitige Erweiterung wird voraussichtlich bis Anfang 2027 abgeschlossen sein. Die Investition umfasst eine Annex 1-konforme Isolator-basierte Abfüllanlage für Fläschchen sowie ein Gefriertrockner nach Anhang 1. Nach Fertigstellung wird Glasgow in der Lage sein, Chargen von bis zu 20.000 Fläschchen abzufüllen, und ist damit gut aufgestellt, um künftige kommerzielle Abfüllungen in kleinem Maßstab durchzuführen.

„Diese Erweiterung in Glasgow erfolgt zu einem Zeitpunkt, an dem Curia kurz vor dem Abschluss der umfangreichen Erweiterung unserer Produktionsstätte für Arzneimittel in Albuquerque, New Mexico, steht“, sagte Ron Aungst, VP, Drug Product Business Unit Operations. „Curia hat bereits entscheidende, mit langen Lieferzeiten verbundene Anlagen gesichert, um den Ausbau in Glasgow im Zeitplan zu halten, und wir rechnen während der Erweiterung nicht mit Beeinträchtigungen des laufenden Betriebs.“

Die Kompetenzen von Curia im Bereich der klinischen Wirkstoffentwicklung wurden zudem durch Verbesserungen an der firmeneigenen Plattform zur Zelllinienentwicklung (CLD) erweitert. Das CLD-Angebot am Standort Hopkinton, Massachusetts, von Curia wurde erweitert und umfasst nun eine IP-freie, halbgerichtete Integrationstechnologie, die im Vergleich zur Technologie der zufälligen Integration zu einem sechsmal höheren Titer führt. Die stabile Plattform von Curia, CHO-GSN®, wurde aus derselben Elternzelllinie entwickelt wie die transiente Plattform TunaCHO®, sodass Partner den Prozess von der Forschung bis zur GMP-Konformität effizient skalieren können.

„Unser Geschäftsbereich Biologika verfügt seit jeher über umfassende Kompetenzen, und wir freuen uns, eine Zelllinie anbieten zu können, die es unseren Partnern ermöglicht, die klinische Herstellung in der Frühphase kostengünstiger und schneller voranzutreiben“, sagte Jamie Grabowski, President, Research & Development. „Dank biotechnologiefreundlicher Lizenzbedingungen wird die neu entwickelte Zelllinie eine entscheidende Rolle dabei spielen, unsere Partner erfolgreich auf ihrem Weg zur Markteinführung zu begleiten.“

Über Curia
Curia ist ein Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen (CDMO) mit über 30 Jahren Erfahrung, einem integrierten Netzwerk von über 20 Standorten weltweit und 3.100 Mitarbeitern, die mit biopharmazeutischen Kunden zusammenarbeiten, um lebensverändernde Therapien auf den Markt zu bringen. Unser Angebot an niedermolekularen, generischen Wirkstoffen und Biologika reicht von der Entdeckung bis zur Vermarktung und umfasst integrierte regulatorische, analytische und sterile Abfüll- und Veredelungskapazitäten. Unsere wissenschaftlichen und technischen Experten bieten zusammen mit unseren regulatorisch konformen Einrichtungen erstklassige Erfahrung in der Herstellung von Arzneimitteln und Produkten. Von der Neugier bis zur Heilung – wir unterstützen Sie bei jedem Schritt, um Ihre Forschung zu beschleunigen und das Leben von Patienten zu verbessern. Besuchen Sie uns unter curiaglobal.com.

Unternehmenskontakt:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9675601)

Curia Expande Capacidade de Fabricação de Glasgow e Aprimora Plataforma de Desenvolvimento de Linhagem Celular

ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato (CDMO), anunciou hoje o progresso na expansão da sua unidade de produtos farmacêuticos estéreis em Glasgow, no Reino Unido, bem como aprimoramentos da sua plataforma proprietária para o desenvolvimento de linhagens celulares.

O local de Glasgow, Reino Unido, é bem conhecido em toda a indústria pelos seus mais de 25 anos de experiência com formulação, desenvolvimento de liofilização e capacidade de acabamento de enchimento estéril, incluindo ADCs e outros produtos altamente potentes. A expansão atual deve ser concluída no início de 2027. O investimento adicionará uma linha de enchimento de frascos baseada em isolador compatível com o Anexo 1 e um liofilizador. Após a expansão, Glasgow terá a capacidade de enchimento de lotes de até 20.000 frascos e estará bem posicionado para dar suporte a futuros enchimentos comerciais em pequena escala.

“Esta expansão de Glasgow ocorre no momento em que a Curia se aproxima da conclusão da significativa expansão da nossa unidade comercial de produtos farmacêuticos em Albuquerque, NM”, disse Ron Aungst, Vice-Presidente de Operações da Unidade de Negócios de Produtos Farmacêuticos. “A Curia já adquiriu equipamentos cruciais com longos prazos de entrega para ajudar a manter o projeto de expansão em Glasgow dentro do cronograma, e não prevemos qualquer interrupção nas operações atuais durante a expansão.”

A capacidade de desenvolvimento clínico de substâncias farmacêuticas da Curia também foi aprimorada com melhorias na plataforma de desenvolvimento de linhagens celulares (CLD) da empresa. A oferta de CLD na unidade da Curia em Hopkinton, MA, foi aprimorada para incorporar uma tecnologia de integração semialvo e sem propriedade intelectual, resultando em títulos seis vezes superiores em comparação à tecnologia de integração aleatória. A CHO-GSN®, a plataforma estável da Curia, foi derivada da mesma linhagem celular parental da sua plataforma transiente, a TunaCHO®, viabilizando que os parceiros realizem o scale-up de forma eficiente, desde a fase de descoberta até a produção em conformidade com as BPF.

“Nossa divisão de produtos biológicos sempre teve total capacidade, e estamos entusiasmados em oferecer uma linhagem celular que torna mais eficiente, em termos de custo e rapidez, o avanço dos nossos parceiros pelas etapas iniciais da fabricação clínica”, disse Jamie Grabowski, Presidente de Pesquisa e Desenvolvimento. “Com termos de licenciamento favoráveis à biotecnologia, a linhagem celular reengenheirada será um componente crítico para orientar com sucesso os parceiros no seu rumo à comercialização.”

Sobre a Curia
A Curia é uma Organização de Desenvolvimento e Fabricação por Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de mais de 20 locais em todo o mundo e 3.100 funcionários em parcerias com clientes biofarmacêuticos para lançamento no mercado terapias que mudam a vida. Nossas ofertas de pequenas moléculas, APIs genéricos e produtos biológicos resultam em descobertas através da comercialização, com integridade regulatória, de capacidade analítica e processamento final estéril. Nossos especialistas científicos e de processos, juntamente com nossas instalações em conformidade regulatórias, oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas necessárias para acelerar sua pesquisa e melhorar a vida dos pacientes. Visite-nos em curiaglobal.com.

Contato Corporativo:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9675601)

Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform

ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development.

The Glasgow, UK, site is well known throughout the industry for its more than 25 years of experience with formulation, lyophilization development and sterile fill-finish capabilities, including ADCs and other highly potent products. The current expansion is expected to be completed by early 2027. The investment will add an Annex 1 compliant isolator-based vial filling line and lyophilizer. Once complete, Glasgow will be able to fill batches up to 20,000 vials and will be well‑positioned to support future small‑scale commercial fills.

“This expansion in Glasgow comes as Curia is nearing completion of our significant expansion in our commercial drug product facility in Albuquerque, NM,” said Ron Aungst, VP, Drug Product Business Unit Operations. “Curia has already secured crucial equipment with long lead times to help the Glasgow expansion project stay on track, and we do not anticipate any disruption to current operations during the expansion.”

Curia’s clinical drug substance development capabilities have also been enhanced with improvements to the company’s cell line development (CLD) platform. The CLD offering at Curia’s Hopkinton, MA facility has been enhanced to incorporate IP-free semi-targeted integration technology that results in 6-fold higher titers compared to random integration technology. Curia’s stable platform, CHO-GSN®, was derived from the same parental cell line as its transient platform, TunaCHO®, allowing partners to efficiently scale-up from discovery to GMP.

“Our biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-efficient and faster to advance partners through early-stage clinical manufacturing,” said Jamie Grabowski, President, Research & Development. “With biotech-friendly licensing terms, reengineered cell line will be a critical component of successfully guiding partners on their path to commercialization.”

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]


GLOBENEWSWIRE (Distribution ID 9674771)

Fortrea erweitert Führungsteam und ernennt Oren Cohen zum Chief Medical Officer und Scott Dove zum President of Clinical Pharmacology Services

DURHAM, North Carolina, Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (das „Unternehmen“), eine weltweit führende Contract Research Organization (CRO), hat heute bekanntgegeben, dass es sein Führungsteam erweitert hat. Oren Cohen, MD, der zuvor sowohl als Chief Medical Officer (CMO) von Fortrea als auch als President of Clinical Pharmacology Services (CPS) tätig war, widmet sich nun ausschließlich seinen Aufgaben als CMO, nämlich der medizinischen Strategie, der wissenschaftlichen Leitung, der Ethik und der Governance-Aufsicht für das gesamte Fortrea-Portfolio. Scott Dove, PhD, ist der neue President of Clinical Pharmacology Services (CPS) bei Fortrea und verantwortlich für die frühen klinischen Entwicklungslösungen in Fortreas globalen Netzwerk von klinischen Forschungseinheiten. Cohen und Dove sind beide Mitglieder des Executive Committee von Fortrea.

„Die Aufnahme von Scott in das Fortrea-Team, während sich Oren nun voll und ganz den medizinischen und wissenschaftlichen Aspekten der Entwicklung widmet, ist ein Gewinn für unsere Kunden“, so Anshul Thakral, CEO. „Durch die enge Zusammenarbeit mit unseren Führungskräften in allen Phasen der klinischen Entwicklung wird Oren seine Beziehungen zu den Kunden vertiefen. Er beteiligt sich früher am wissenschaftlichen Dialog und arbeitet eng mit unseren Ärzten und therapeutischen Führungskräften zusammen, um komplexe Entwicklungsherausforderungen zu bewältigen und dabei die höchsten Standards der wissenschaftlichen Integrität und Patientensicherheit aufrechtzuerhalten. Scott hat sich schnell in unser Team für klinische Pharmakologie eingearbeitet und gewinnt derzeit einen direkten Einblick in unsere erstklassigen Kliniken. Er vereint einen starken technischen Hintergrund in der klinischen Entwicklung und im operativen Bereich mit einer erfolgreichen Führungsbilanz beim Aufbau und der Leitung globaler Organisationen. Ich freue mich auf seine Impulse zur weiteren Stärkung unseres Angebots.“

Oren Cohen, MD Chief Medical Officer

Oren Cohen, MD, ist ein erfahrener Experte in der Arzneimittelentwicklung und verfügt über mehr als 20 Jahre Erfahrung in verschiedenen leitenden medizinischen und wissenschaftlichen Funktionen der pharmazeutischen Industrie. Vor seiner Tätigkeit bei Fortrea war er als CMO und Head of Clinical Pharmacology Services bei Labcorp Drug Development tätig. Zuvor war er CMO bei Viamet Pharmaceuticals und hatte verschiedene leitende Positionen im medizinischen und operativen Bereich bei Quintiles inne, das heute zu IQVIA gehört.

Dr. Cohen erhielt seinen MD an der Duke University und absolvierte seine Facharztausbildung am New York Hospital, Cornell Medical Center, in New York City. Er absolvierte seine Schwerpunktweiterbildung (Fellowship) im Bereich Infektionskrankheiten am National Institute of Allergy and Infectious Diseases, wo er als Principal Investigator tätig war und als stellvertretender Direktor für medizinische Angelegenheiten des Instituts fungierte. Er ist Consulting Professor für Medizin am Duke University Medical Center, Mitglied des Board of Visitors der Duke University School of Medicine und Fellow der Infectious Diseases Society of America.

Scott Dove, PhD President Clinical Pharmacology Services

Scott Dove, PhD, bringt mehr als 25 Jahre Erfahrung in der Arzneimittelentwicklung zu Fortrea mit und war in verschiedenen Positionen mit zunehmender Verantwortung bei Pharma-, Biotech- und CRO-Unternehmen tätig. Zuletzt fungierte er als Berater für verschiedene Unternehmen, darunter auch Fortrea. Zuvor war Dr. Dove Chief Operating Officer bei Aravive, wo er die Forschungs- und Entwicklungsaktivitäten eines Onkologie-Biotech-Unternehmens in der klinischen Entwicklungsphase leitete. Darüber hinaus war er mehr als zehn Jahre lang in Führungspositionen bei PPD beschäftigt und war dort Leiter des Bereichs der frühen klinischen Entwicklung. Dr. Dove hatte außerdem Führungspositionen bei Allergan und Furiex Pharmaceuticals inne.

Dr. Dove promovierte am Texas A&M Health Science Center und erwarb seinen Bachelor of Science in Biochemie an der Texas A&M University.

Über Fortrea

Fortrea (Nasdaq: FTRE) ist ein weltweit führender Anbieter von Lösungen für die klinische Entwicklung in der Life-Sciences-Branche. Um Innovationen im Gesundheitswesen voranzutreiben und das Angebot lebensverändernder Therapien für Patienten zu beschleunigen, arbeiten wir mit aufstrebenden und großen biopharmazeutischen, biotechnologischen, medizintechnischen und diagnostischen Unternehmen zusammen. Fortrea bietet das Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie sowie Beratungsdienste an. Die Lösungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft für wissenschaftliche Strenge, außergewöhnlichen Erkenntnissen und einem starken Netzwerk von Prüfzentren. Unser talentiertes und vielfältiges Team, das in etwa 100 Ländern tätig ist, ist darauf ausgelegt, Kunden weltweit fokussierte und flexible Lösungen zu bieten. Erfahren Sie mehr darüber, wie Fortrea zu einer transformativen Kraft von der Pipeline bis zum Patienten wird, unter Fortrea.com und folgen Sie uns auf LinkedIn und X (ehemals Twitter).

Fortrea-Ansprechpartner:
Tracy Krumme (Investoren) – 984-385-6707, [email protected]
Sue Zaranek (Medien) – 919-943-5422, [email protected]
Kate Dillon (Medien) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

Fortrea Expande Equipe Executiva, Nomeia Oren Cohen como Diretor Médico e Scott Dove como Presidente dos Serviços de Farmacologia Clínica

DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje a expansão da sua equipe executiva. Oren Cohen, MD, ex-diretor médico (CMO) da Fortrea e presidente dos Serviços de Farmacologia Clínica (CPS), agora se dedica à sua responsabilidade de CMO, ou seja, estratégia médica, liderança científica, ética e supervisão de governança em todo o portfólio da Fortrea. Scott Dove, PhD, junta-se à Fortrea como novo presidente de CPS, responsável pelas primeiras soluções de desenvolvimento clínico da Fortrea em toda a sua rede global de unidades de pesquisa clínica. Cohen e Dove atuam no Comitê Executivo da Fortrea.

“A entrada de Scott para a equipe da Fortrea e a dedicação total de Oren aos aspectos médicos e científicos do desenvolvimento, é uma vitória para os clientes”, disse Anshul Thakral, CEO. “Com seu trabalho em estreita colaboração com nossos líderes de negócios em todas as fases do desenvolvimento clínico, Oren irá aprofundar seu relacionamento com os clientes. Ele já está envolvido no diálogo científico e colaborando estreitamente com nossos médicos e líderes terapêuticos para ajudar a enfrentar desafios complexos de desenvolvimento, mantendo os mais altos padrões de integridade científica e segurança do paciente. Scott está se entrosando com a nossa equipe de Farmacologia Clínica e tendo uma visão em primeira mão de nossas clínicas de classe mundial. Ele tem uma sólida formação técnica em desenvolvimento clínico e operações e um histórico de sucessos na liderança da criação e liderança de organizações globais. Mal posso esperar por suas ideias sobre devemos fortalecer ainda mais nossa oferta.”

Oren Cohen, MD Diretor Médico

Oren Cohen, MD, é veterano do desenvolvimento de medicamentos, com mais de 20 anos de experiência em várias funções de liderança executiva médica e científica na indústria farmacêutica. Antes da Fortrea, o Dr. Cohen atuou como CMO e chefe dos Serviços de Farmacologia Clínica da Labcorp Drug Development. Anteriormente, foi CMO da Viamet Pharmaceuticals e atuou em vários cargos de liderança médica e operacional sênior na Quintiles, agora parte da IQVIA.

O Dr. Cohen é formado pela Duke University, fez seu estágio e residência no The New York Hospital, Cornell Medical Center, em Nova York. Ele completou sua bolsa em Doenças Infecciosas no Instituto Nacional de Alergia e Doenças Infecciosas, onde permaneceu como Investigador Principal e atuou como diretor assistente de assuntos médicos do instituto. Ele é Professor Consultor de Medicina do Duke University Medical Center, membro do Conselho de Visitantes da Duke University School of Medicine e Fellow da Infectious Diseases Society of America.

Scott Dove, PhD Presidente Serviços de Farmacologia Clínica

Scott Dove, PhD, traz mais de 25 anos de experiência em desenvolvimento de medicamentos para a Fortrea, tendo atuado em funções de responsabilidade crescente em empresas farmacêuticas, de biotecnologia e CRO. Recentemente, ele atuou como consultor de várias empresas, incluindo a Fortrea. Anteriormente, o Dr. Dove foi diretor de operações da Aravive, liderando as operações de P&D em um estágio clínico de biotecnologia focada em oncologia. Ele também atuou em cargos de liderança na PPD durante mais de uma década, onde liderou serviços de desenvolvimento inicial. O Dr. Dove também ocupou cargos de liderança na Allergan e na Furiex Pharmaceuticals.

O Dr. Dove recebeu seu PhD do Texas A&M Health Science Center e obteve seu bacharelado em bioquímica na Texas A&M University.

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica e serviços de consultoria. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada que trabalha em cerca de 100 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para pacientes em Fortrea.com e siga-nos em LinkedIn e X (ex-Twitter).

Contatos da Fortrea:
Tracy Krumme (Investidores) – 984-385-6707, [email protected]
Sue Zaranek (Mídia) – 919-943-5422, [email protected]
Kate Dillon (Mídia) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

Fortrea renforce son équipe de direction en nommant Oren Cohen au poste de directeur médical et Scott Dove à celui de président des services de pharmacologie clinique

DURHAM, Caroline du Nord, 17 févr. 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE) (la « Société »), une organisation mondiale de recherche sous contrat (CRO) de premier plan, annonce ce jour l’élargissement de son équipe de direction. Oren Cohen, MD, qui occupait auparavant les fonctions de directeur médical (CMO) et de président des services de pharmacologie clinique (CPS) chez Fortrea, se consacre désormais à ses responsabilités de directeur médical, à savoir la stratégie médicale, le leadership scientifique, l’éthique et la supervision de la gouvernance à l’échelle de l’ensemble du portefeuille de Fortrea. Scott Dove, PhD, rejoint Fortrea en qualité de nouveau président des CPS. Il sera chargé de piloter les solutions de développement clinique précoce de l’entreprise au sein de son réseau mondial d’unités de recherche clinique. M. Cohen et M. Dove siègent tous deux au comité exécutif de Fortrea.

« L’arrivée de Scott au sein de l’équipe de Fortrea, tandis qu’Oren se consacre pleinement aux dimensions médicales et scientifiques du développement, constitue un atout majeur pour les clients », a déclaré Anshul Thakral, PDG. « En collaborant étroitement avec nos responsables commerciaux à chaque étape du développement clinique, Oren consolidera ses relations avec les clients. Il intervient plus en amont dans les échanges scientifiques et travaille en étroite collaboration avec nos médecins et responsables thérapeutiques afin de répondre aux défis complexes du développement, tout en veillant au respect des normes les plus strictes en matière d’intégrité scientifique et de sécurité des patients. Scott s’intègre rapidement à notre équipe de pharmacologie clinique et se familiarise de près avec nos cliniques de renommée internationale. Il associe une expertise technique approfondie en développement clinique et en opérations à une solide expérience de leadership dans la création et la gestion d’organisations internationales. Je me réjouis de pouvoir m’appuyer sur ses idées pour continuer à renforcer notre offre. »

Oren Cohen, MD, directeur médical

Le Dr Oren Cohen est un professionnel chevronné du développement de médicaments, fort de plus de 20 ans d’expérience dans des fonctions de direction médicale et scientifique au sein de l’industrie pharmaceutique. Avant de rejoindre Fortrea, le Dr Cohen a exercé les fonctions de directeur médical et de responsable des services de pharmacologie clinique chez Labcorp Drug Development. Auparavant, il a exercé en tant que directeur médical chez Viamet Pharmaceuticals et a occupé plusieurs postes de direction médicale et opérationnelle de haut niveau chez Quintiles, qui fait désormais partie d’IQVIA.

Le Dr Cohen est titulaire d’un doctorat en médecine de l’Université Duke et a effectué son internat et son résidanat au New York Hospital, Cornell Medical Center, à New York. Il a effectué son stage postdoctoral en maladies infectieuses à l’Institut national des allergies et des maladies infectieuses, où il est ensuite resté en qualité d’investigateur principal et a occupé le poste de directeur adjoint des affaires médicales de l’institut. Il est professeur consultant en médecine au Duke University Medical Center, membre du conseil d’administration de la faculté de médecine de l’université Duke et membre de l’Infectious Diseases Society of America.

Scott Dove, PhD, président des services de pharmacologie clinique

Scott Dove, PhD, rejoint Fortrea avec plus de 25 ans d’expérience dans le développement de médicaments, au cours desquels il a exercé des fonctions à responsabilités croissantes dans des entreprises pharmaceutiques, biotechnologiques et des CRO. Plus récemment, il a exercé en tant que conseiller pour plusieurs entreprises, y compris Fortrea. Auparavant, le Dr Dove a occupé le poste de directeur des opérations chez Aravive, où il supervisait les opérations de R&D d’une société de biotechnologie en phase clinique spécialisée en oncologie. Il a également exercé des fonctions de direction chez PPD pendant plus de dix ans, supervisant les services de développement clinique précoce. Le Dr Dove a par ailleurs exercé des fonctions de direction chez Allergan et Furiex Pharmaceuticals.

Le Dr Dove a obtenu son doctorat au Texas A&M Health Science Center et sa licence en biochimie à l’Université A&M du Texas.

À propos de Fortrea

Fortrea (Nasdaq : FTRE) est un fournisseur mondial de premier plan de solutions de développement clinique pour le secteur des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, de la biotechnologie, des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients. Fortrea propose des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique et de consulting. Nos solutions s’appuient sur 30 ans d’expérience dans 20 disciplines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée, qui travaille dans près de 100 pays, est dimensionnée pour fournir des solutions ciblées et flexibles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea est un moteur d’influence du pipeline au patient, rendez-vous sur Fortrea.com et suivez-nous sur LinkedIn et X (anciennement Twitter).

Contacts Fortrea :
Tracy Krumme (Investisseurs) – 984-385-6707, [email protected]
Sue Zaranek (Médias) – 919-943-5422, [email protected]
Kate Dillon (Médias) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea’s portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea’s early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea’s Executive Committee.

“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO. “Working closely with our business leaders across all phases of clinical development, Oren will deepen his relationships with clients. He’s engaging earlier in scientific dialogue and collaborating closely with our physicians and therapeutic leaders to help address complex development challenges, all while upholding the highest standards of scientific integrity and patient safety. Scott is making a fast start with our Clinical Pharmacology team and is getting a first-hand view of our world-class clinics. He combines a strong technical background in clinical development and operations with a successful track record of leadership in building and leading global organizations, and I’m looking forward to his insights on how we further strengthen our offering.”

Oren Cohen, MD Chief Medical Officer

Oren Cohen, MD is a veteran of drug development, bringing more than 20 years of experience in various medical and scientific executive leadership roles in the pharmaceutical industry. Prior to Fortrea, Dr. Cohen served as CMO and head of Clinical Pharmacology Services at Labcorp Drug Development. Previously, he was CMO at Viamet Pharmaceuticals and served in several senior medical and operational leadership positions at Quintiles, now part of IQVIA.

Dr. Cohen received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases, where he stayed as a Principal Investigator and served as the institute's assistant director for medical affairs. He is a Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine and a Fellow of the Infectious Diseases Society of America.

Scott Dove, PhD President Clinical Pharmacology Services

Scott Dove, PhD brings more than 25 years of drug development experience to Fortrea, serving in roles of increasing responsibility at pharma, biotech and CRO companies. Most recently, he has served as an advisor to a variety of companies, including Fortrea. Previously, Dr. Dove was chief operating officer at Aravive, leading R&D operations for a clinical stage, oncology-focused biotech. He also served in leadership roles at PPD for more than a decade, where he led early development services. Dr. Dove also held leadership roles at Allergan and Furiex Pharmaceuticals.

Dr. Dove received his PhD from Texas A&M Health Science Center and earned his bachelor of science in biochemistry at Texas A&M University.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).                    

Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]
          


GLOBENEWSWIRE (Distribution ID 9655383)